Kolltan Pharmaceuticals

Kolltan develops and commercializes antibody-based drugs targeting Receptor Tyrosine Kinases for the treatment of cancer.

Business Model:

Revenue: $10M

Employees: 11-50

Rankings

Detailed Kolltan Pharmaceuticals Information

Kolltan Pharmaceuticals was acquired by Celldex Therapeutics.
The acquisition happend on 2016-11-01.
Details of the transaction were not public

Geographic Data

Kolltan Pharmaceuticals headquarters map

Address: 300 George St

City: New Haven

State: CT

Zip: 06511

Country: US

Financial Info

Stage:

series d

Raised Last:

$60M

Raised Total:

$91M

Metrics

0Website Global Rank

0Website Monthly Traffic

Twitter Followers

Description

Kolltan develops and commercializes antibody-based drugs targeting Receptor Tyrosine Kinases for the treatment of cancer.

Contact Phone:
+12037733000

Contact Email:

Kolltan Pharmaceuticals went public on the NASDAQ

Listed Exchange:
NASDAQ

Ticker Symbol:
KLTN

Live

Opened: -/share

EBITDA -
Total Cash -
Total Debt -
Total Revenue -
Total Profit (Gross) -
PE Ratio -
Announced Date Company Transaction Money Raised
Announced Date Name Price

Employee Departments

Employee States

Uniview Singapore VEID Logo
Uniview Singapore VEID
Revenue: 0 - 100000
Employees:
Industry: Software
Details
Konkuk University Medical Center Logo
Konkuk University Medical Center
Revenue: 0 - 100000
Employees: 51 - 500
Industry: Education
Details
Daemon Technologies Logo
Daemon Technologies
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Blockchain
Details
Ace International Trade Logo
Ace International Trade
Revenue: 0 - 100000
Employees: 11 - 50
Industry: Industrial
Details
An Hòa Communications Logo
An Hòa Communications
Revenue: 0 - 100000
Employees: 1 - 10
Industry: Advertising
Details

You know, we could be doing all this for you..

CoBee's Logo

Be ahead of your competition

  • Realtime intelligence
  • Automated contact tracking
  • Unmatched insights
  • Eliminate manual research